We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

By LabMedica International staff writers
Posted on 24 Apr 2023
Print article
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes a significant economic burden on global healthcare systems. Numerous studies have established connections between various cardiovascular diseases and specific protein biomarkers in the blood. However, current methods for analyzing these protein biomarkers, such as ELISA or western blot assays, involve multistep, reagent-intensive processes and require specialized laboratory equipment, limiting their practical applicability and resulting in delayed treatment, reduced compliance, and worse outcomes. Consequently, there is an urgent need for novel methods that enable direct, reagent-free analysis of molecular analytes to identify cardiovascular abnormalities in their early stages and prevent or mitigate their progression.

A team of researchers at University of Toronto (Ontario, Canada) and Northwestern University (Evanston, IL, USA) has designed an electronic biosensor utilizing DNA aptamers to detect biomarkers in whole blood samples without the need for additional reagents. These DNA aptamers recognize marker proteins as effectively as antibodies, but they are simpler to produce and more versatile. The biosensor successfully identified clinically relevant levels of a cardiovascular disease marker protein without further sample preparation.

The researchers' goal was to create diagnostic tools capable of directly, reliably, and in-field detection of disease biomarkers, eliminating the need to send samples to specialized labs for analysis. The chip-based device developed by the researchers employs chronoamperometric measurements to identify marker proteins in complex samples. Their nanoscale sensor system functions as a molecular "pendulum," measuring the extra load a protein places on the pendulum, which consists of a DNA strand attached to an electrode, without requiring external reagents.

While antibodies are typically used to locate and bind marker proteins in complex mixtures, their complexity makes designing and producing them a challenge. Instead, researchers found that smaller, simpler DNA aptamers can be used as alternatives to antibodies. DNA aptamers are short synthetic fragments with specific shapes and structures, relatively easy and inexpensive to produce, and their structures can be customized. Like antibodies, DNA aptamers can bind marker proteins through molecular and structural interactions but are simpler to design.

The researchers developed an aptamer-based sensor by creating a DNA aptamer specific to B-type natriuretic peptide (BNP), a cardiovascular disease biomarker, and connecting it to the DNA pendulum strand tethered to a gold electrode, forming the molecular pendulum sensor. This biosensor effectively detected BNP, even in complex samples such as unprocessed whole blood from cardiac patients. As the sensitivity of the aptamer-based system was found to be comparable to that of antibody-based detection, the researchers recommend further exploration and adoption of DNA aptamers for laboratory-independent diagnostics.

Related Links:
University of Toronto 
Northwestern University 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more